Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis.
Duggan P, Booth K, Chaudhry A, Stewart D, Ruether JD, Glück S, Morris D, Brown CB, Herbut B, Coppes M, Anderson R, Wolff J, Egeler M, Desai S, Turner AR, Larratt L, Gyonyor E, Russell JA; Alberta Blood and Bone Marrow Transplant Program. Duggan P, et al. Bone Marrow Transplant. 2002 Nov;30(10):681-6. doi: 10.1038/sj.bmt.1703674. Bone Marrow Transplant. 2002. PMID: 12420207
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, Quinlan D, Stewart D. Russell JA, et al. Biol Blood Marrow Transplant. 2007 Mar;13(3):299-306. doi: 10.1016/j.bbmt.2006.10.017. Biol Blood Marrow Transplant. 2007. PMID: 17317583 Free article. Clinical Trial.
The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.
Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA. Russell JA, et al. Biol Blood Marrow Transplant. 2010 Apr;16(4):509-14. doi: 10.1016/j.bbmt.2009.11.017. Epub 2009 Dec 3. Biol Blood Marrow Transplant. 2010. PMID: 19948235 Free article.
Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts.
Dabas R, Lee R, Servito MT, Dharmani-Khan P, Modi M, van Slyke T, Luider J, Durand C, Larratt L, Brandwein J, Morris D, Daly A, Khan FM, Storek J. Dabas R, et al. Biol Blood Marrow Transplant. 2016 May;22(5):815-24. doi: 10.1016/j.bbmt.2016.01.002. Epub 2016 Jan 9. Biol Blood Marrow Transplant. 2016. PMID: 26779931 Free article. Clinical Trial.
Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
Russell JA, Larratt L, Brown C, Turner AR, Chaudhry A, Booth K, Woodman RC, Wolff J, Valentine K, Stewart D, Ruether JD, Ruether BA, Klassen J, Jones AR, Gyonyor E, Egeler M, Dunsmore J, Desai S, Coppes MJ, Bowen T, Anderson R, Poon MC. Russell JA, et al. Bone Marrow Transplant. 1999 Dec;24(11):1177-83. doi: 10.1038/sj.bmt.1702051. Bone Marrow Transplant. 1999. PMID: 10642805 Clinical Trial.
66 results